Biopharmaceutical Product Attributes and Biological Consequences Community

 View Only

MPA Working Community - MEETING SUMMARY and Action Items from September 15, 2022 Telecon

  • 1.  MPA Working Community - MEETING SUMMARY and Action Items from September 15, 2022 Telecon

    Community Leadership
    Posted 09-19-2022 10:35
    Greetings!
    See below a brief summary and action items from the Sep 15, 2022 meeting of MPA Working Community

    Attendees:

    Josh Katz, Josh Tokuda, Bivash Mandal, Ehab Moussa, Duohai Pan, Danny Chou, Tapan Das

     Meeting summary and Action items:

    1. Attending PharmSci360 at Boston – Some of us are attending and we will meet adhoc. PABC Community is not hosting a scheduled community meeting.
    2. SUBMIT programming ideas for NBC2023 at Philadelphia. Due date is this Thursday, Sept 22 (5pm US eastern). Here is the link – NBC 2023. The following ideas were discussed. Please draft a proposal and submit.
      1. Coformulation – formulation and analytics challenges and recent successes – Bivash?
      2. ADC – new concepts in engineering and design of linker/payload/peptide to address high degree of chemical and physical stability issues – Josh Tokuda and Duohai?
      3. Bispecifics and multispecifics – emerging modality and associated formulation/process/analytical challenges – NEED a submitter
      4. AAV aggregation – frozen vs Lyo – Ehab
      5. Protein aggregation mechanism – emerging concepts in nucleation and how to control – Danny?
    3. Topic for future brainstorming: Coformulation – proposed by Bivash – we initiated the brainstorming a few months back. We will further refine the topic with outstanding questions on choice of excipients, predicting interactions, coformulation analytics challenges etc. To cover more details in the next MPA meeting.

     Sorry about meeting logistical difficulties – Thanks to those who were able to join us.



    ------------------------------
    Tapan Das, Ph.D., FAAPS
    Bristol Myers Squibb


    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer
    ------------------------------